Lipella Pharmaceuticals Files 8-K
Ticker: LIPO · Form: 8-K · Filed: Dec 6, 2024 · CIK: 1347242
| Field | Detail |
|---|---|
| Company | Lipella Pharmaceuticals Inc. (LIPO) |
| Form Type | 8-K |
| Filed Date | Dec 6, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, disclosure
TL;DR
Lipella Pharma filed an 8-K, something happened, details TBD.
AI Summary
Lipella Pharmaceuticals Inc. filed an 8-K on December 6, 2024, to report other events. The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This filing indicates a material event has occurred for Lipella Pharmaceuticals, requiring disclosure to investors, though the specifics are not yet detailed.
Risk Assessment
Risk Level: medium — The filing is an 8-K, which typically signals significant corporate events, but the lack of specific details in this instance creates uncertainty.
Key Players & Entities
- Lipella Pharmaceuticals Inc. (company) — Registrant
- December 6, 2024 (date) — Filing Date
FAQ
What specific event(s) are being reported in this 8-K filing?
The filing does not specify the exact nature of the 'Other Events' being reported, only that an 8-K was filed on December 6, 2024.
When was this 8-K filing submitted?
The 8-K filing was submitted on December 6, 2024.
What is the principal executive office address for Lipella Pharmaceuticals Inc.?
The principal executive office is located at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.
What is the telephone number for Lipella Pharmaceuticals Inc.?
The registrant's telephone number, including area code, is (412) 894-1853.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-12-06 16:05:36
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share LIPO The Nasdaq Stock Mar
Filing Documents
- g084585_8k.htm (8-K) — 32KB
- 0001753926-24-002047.txt ( ) — 202KB
- lipo-20241206.xsd (EX-101.SCH) — 3KB
- lipo-20241206_lab.xml (EX-101.LAB) — 33KB
- lipo-20241206_pre.xml (EX-101.PRE) — 22KB
- g084585_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 6, 2024 Lipella Pharmaceuticals Inc. By: /s/ Jonathan Kaufman Name: Jonathan Kaufman Title: Chief Executive Officer